Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial of pazopanib for soft tissue sarcoma that has got worse during or after other treatment (PALETTE, EORTC 62072)
If soft tissue sarcoma spreads to somewhere else in the body, doctors may treat it with chemotherapy. But sometimes the sarcoma continues to grow or comes back after treatment and more chemotherapy may not help.
Pazopanib is a type of biological therapy called a tyrosine kinase inhibitor (MultiTKI). It works by blocking certain proteins called vascular endothelial growth factors (VEGFs). These are natural body chemicals that control cell growth. Blocking the growth factors may stop cancer growing.
This is the second trial of pazopanib for people with soft tissue sarcoma. The first one showed that pazopanib seemed to slow down or stop the growth in some people.
The aim of this trial was to see if pazopanib helped people with soft tissue sarcoma that had spread and had grown or came back despite other treatment.
Summary of results
The trial team found that pazopanib could help people with soft tissue sarcoma that had spread and had grown or came back despite other treatment.
Of the 369 people recruited to this trial
- 246 had pazopanib
- 123 had a dummy drug (placebo)
The average time it took for the sarcoma to start growing again was
- Just over 4½ months for those who had pazopanib
- Just over 1½ months for those who had the dummy drug
Overall the average length of time people lived was
- 12½ months for those who had pazopanib
- Just over 10½ months for those who had the dummy drug
The main side effects reported were
The researchers concluded that pazopanib could help people with soft tissue sarcoma that had spread and had grown or came back despite other treatment.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Michael Leahy
European Organisation for Research and Treatment of Cancer (EORTC)
Experimental Cancer Medicine Centre (ECMC)
National Institute for Health Research Cancer Research Network (NCRN)